Star Therapeutics secures $200 million to refocus pipeline

Star Therapeutics has secured $200 million in new venture capital financing to return to stealth mode and refocus on its core pipeline of novel biologics for rare diseases. The funding, announced on October 23, 2026, will support the advancement of its lead Phase 3 program for von Willebrand disease and a shift toward developing hard-to-replicate molecules.

The financing round was co-led by OrbiMed and Janus Henderson Investors. It follows Incyte's July 2026 acquisition of Star's subsidiary, Vega Therapeutics, in a deal valued at up to $2 billion. That acquisition included Star's lead asset, the monoclonal antibody latarcibart, also known as VGA039.

Financing details and investor backing

The $200 million financing round attracted participation from a wide array of major biotechnology investors. The capital infusion marks a strategic reset for the company as it moves past its subsidiary model.

CEO Adam Rosenthal described the financing as a reset for the company. He stated the firm's new direction plainly. "We want to be thought of as Star, a biotech company with a great team and pipeline," Rosenthal said, moving away from an emphasis on branded spinouts.

Company background and strategic shift

Founded in 2018, Star Therapeutics was built around experimental drugs for rare diseases with significant unmet need. The company previously operated by creating subsidiaries to develop assets that might struggle in traditional biotech settings. The sale of Vega Therapeutics to Incyte and the September 2026 initial public offering of another spinout, Electra Therapeutics, which raised $350 million, have now provided capital and clarity.

This strategic shift sees Star concentrating on discovering new biologics for hematological and immune conditions that are difficult to copy. The team, which has contributed to four successful acquisitions including Vega Therapeutics, DICE Therapeutics, True North Therapeutics, and iPierian, will now focus its internal efforts. Rosenthal noted that while the company could have commercialized its von Willebrand disease treatment independently, Incyte's offer provided superior clinical and commercial capabilities.

Pipeline and future plans

The immediate focus is on advancing latarcibart through Phase 3 development for von Willebrand disease. Beyond this lead program, the new funding will enable Star to study an undisclosed number of experimental biologics. The company plans to advance its current preclinical programs into clinical trials and continue expanding its pipeline.

The financing supports Star's next phase of growth entirely in-house. The plan is to build a pipeline of novel, hard-to-replicate molecules rather than improving upon existing drugs. The company closes this chapter of subsidiary sales and public offerings by advancing preclinical work into the clinic for hematological and immune conditions.